Incidence of Infections While in Remission by Response to Fludarabine
| Infection . | CR (51 patients) . | PR-Nod (56 patients) . | PR (30 patients) . | Total (137 patients) . |
|---|---|---|---|---|
| Pneumonia | 2 (0.01) | 5 (0.04) | 5 (0.13) | 12 (0.04) |
| Septicemia | 0 (—) | 0 (—) | 1 (0.03) | 1 (0.003) |
| Sino-bronchial | 3 (0.02) | 6 (0.05) | 6 (0.16) | 15 (0.05) |
| Upper respiratory | 3 (0.02) | 6 (0.05) | 4 (0.10) | 13 (0.04) |
| Influenza | 3 (0.02) | 3 (0.03) | 0 (—) | 6 (0.02) |
| Minor/FUO | 6 (0.04) | 3 (0.03) | 4 (0.10) | 13 (0.04) |
| Herpes simplex | 2 (0.01) | 3 (0.03) | 0 (—) | 5 (0.02) |
| Herpes zoster | 10 (0.06) | 8 (0.07) | 1 (0.03) | 19 (0.06) |
| Urinary | 5 (0.03) | 4 (0.03) | 1 (0.03) | 10 (0.03) |
| Total | 34 (0.22) | 38 (0.32) | 22 (0.57) | 94 (0.30) |
| Patient years at risk | 157.44 | 117.33 | 38.55 | 313.32 |
| Infection . | CR (51 patients) . | PR-Nod (56 patients) . | PR (30 patients) . | Total (137 patients) . |
|---|---|---|---|---|
| Pneumonia | 2 (0.01) | 5 (0.04) | 5 (0.13) | 12 (0.04) |
| Septicemia | 0 (—) | 0 (—) | 1 (0.03) | 1 (0.003) |
| Sino-bronchial | 3 (0.02) | 6 (0.05) | 6 (0.16) | 15 (0.05) |
| Upper respiratory | 3 (0.02) | 6 (0.05) | 4 (0.10) | 13 (0.04) |
| Influenza | 3 (0.02) | 3 (0.03) | 0 (—) | 6 (0.02) |
| Minor/FUO | 6 (0.04) | 3 (0.03) | 4 (0.10) | 13 (0.04) |
| Herpes simplex | 2 (0.01) | 3 (0.03) | 0 (—) | 5 (0.02) |
| Herpes zoster | 10 (0.06) | 8 (0.07) | 1 (0.03) | 19 (0.06) |
| Urinary | 5 (0.03) | 4 (0.03) | 1 (0.03) | 10 (0.03) |
| Total | 34 (0.22) | 38 (0.32) | 22 (0.57) | 94 (0.30) |
| Patient years at risk | 157.44 | 117.33 | 38.55 | 313.32 |
Incidence is the number of episodes per patient years at risk. Values are the number of episodes with the incidence in parentheses.